British vaccine proved ineffective against COVID-19 strain from South Africa
The effectiveness of the coronavirus vaccine developed by the British pharmaceutical company AstraZeneca in collaboration with the University of Oxford was low from the COVID-19 strain found in South Africa. This is reported by the Financial Times.
The publication conducted a study on two thousand people, as a result, it turned out that the injection of the vaccine from AstraZeneca probably does not provide protection in the mild to moderate course of the disease caused by the virus from South Africa.
At the same time, the effectiveness of the drug against a severe form of the disease and its effect on mortality when infected with the South African strain has not yet been studied.
However, the publication emphasizes that the study may be incomplete since its scale was not too large. Tulio de Oliveira, head of South Africa's Genomic Surveillance System, said the findings were a wake-up call that calls for increased control of COVID-19 worldwide.
A new strain of coronavirus was discovered in South Africa on December 18. Scientists have identified a previously unknown type of SARS-CoV-2 virus in the country. The Minister of Health of South Africa stressed that the second wave of coronavirus in the country is probably associated with this mutation of the disease.
TAGS: CORONAVIRUS, VACCINE, COVID-19